KITABIS PAK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KITABIS PAK (KITABIS PAK).
Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and incorporation of incorrect amino acids into the peptide chain.
| Metabolism | Primarily eliminated unchanged by glomerular filtration; minimal hepatic metabolism. |
| Excretion | Primarily renal (90% as unchanged drug) via glomerular filtration and tubular secretion; biliary/fecal elimination accounts for <10%. |
| Half-life | 3-4 hours in patients with normal renal function; prolonged to 20-40 hours in anuria. Clinical context: Dosing interval adjustment required for CrCl <30 mL/min. |
| Protein binding | 0-10%; primarily binds to albumin and α1-acid glycoprotein. |
| Volume of Distribution | 0.23-0.35 L/kg; indicates distribution primarily into extracellular fluid. Clinical meaning: Low Vd correlates with poor penetration into cells and CNS. |
| Bioavailability | Oral: <1%; IM: 50-60%; nebulized: lung deposition 10-15% of nominal dose, with negligible systemic bioavailability (<1%). |
| Onset of Action | IM: 30 minutes; IV: immediately; inhalation (nebulized): 15 minutes. |
| Duration of Action | IM/IV: 6-8 hours; inhalation: 6-12 hours. Clinical note: Sustained lung concentrations with nebulized therapy, but systemic levels minimal. |
Inhaled tobramycin: 300 mg twice daily, 28 days on, 28 days off. Administered via nebulizer.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for GFR >= 50 mL/min. For GFR < 50 mL/min: use with caution; consider monitoring serum tobramycin concentrations. For GFR < 30 mL/min: not recommended. |
| Liver impairment | No specific dose adjustment required; tobramycin is primarily renally eliminated. Caution in severe hepatic impairment due to potential concurrent renal dysfunction. |
| Pediatric use | Children aged 6 years and older: 300 mg twice daily via nebulizer. For children <6 years: safety and efficacy not established. |
| Geriatric use | No specific dose adjustment based on age alone. Monitor renal function and adjust dose according to GFR. Increased risk of ototoxicity and nephrotoxicity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for KITABIS PAK (KITABIS PAK).
| Breastfeeding | Tobramycin is excreted into human breast milk in low concentrations after systemic administration. Inhaled tobramycin results in negligible systemic levels; M/P ratio not established for inhaled route. Based on limited data, the American Academy of Pediatrics considers tobramycin compatible with breastfeeding. However, caution is advised due to potential for alteration of infant gut flora and direct infant exposure. Monitor infant for diarrhea or rash. |
| Teratogenic Risk | KITABIS PAK (tobramycin inhalation solution) is an aminoglycoside antibiotic. Animal studies have shown evidence of ototoxicity and nephrotoxicity in fetuses following high-dose systemic administration. However, inhaled tobramycin results in minimal systemic absorption. FDA Pregnancy Category D: Positive evidence of human fetal risk but potential benefits may warrant use in pregnant women with cystic fibrosis. First trimester: Theoretical risk of ototoxicity; use only if clearly needed. Second/third trimester: Risk of fetal ototoxicity and nephrotoxicity with systemic accumulation; pulmonary delivery reduces risk. Avoid if alternative antibiotics available. |
■ FDA Black Box Warning
May cause nephrotoxicity, ototoxicity, and neuromuscular blockade. Monitor renal function and hearing. Avoid concurrent use with other nephrotoxic or ototoxic drugs.
| Serious Effects |
Hypersensitivity to tobramycin or any aminoglycoside; pre-existing severe renal disease; current or previous history of hearing loss.
| Precautions | Monitor renal function, eighth cranial nerve function, and serum drug levels. Use caution in patients with renal impairment, myasthenia gravis, or hypocalcemia. Increased risk of nephrotoxicity with prolonged use or high doses. |
Loading safety data…
| Fetal Monitoring | Baseline and periodic audiometry (especially high-frequency) and renal function tests (serum creatinine, BUN) in mother. Monitor serum tobramycin levels if systemic absorption suspected (e.g., concurrent IV antibiotics). Fetal monitoring: Serial ultrasound for growth and amniotic fluid volume if used long-term. Assess for fetal ototoxicity (hearing assessment after birth if significant exposure). |
| Fertility Effects | No specific human studies on fertility; animal studies with systemic aminoglycosides have shown no impairment of fertility. Inhaled tobramycin has limited systemic absorption, making direct reproductive toxicity unlikely. However, underlying cystic fibrosis may affect fertility independent of drug. |